| Year |
Citation |
Score |
| 2020 |
Vogel CW, Hew BE, Fritzinger DC. Identification of functionally important amino acid residues for C3 convertase activity using chimeric proteins of human C3 and cobra venom factor. Toxicon : Official Journal of the International Society On Toxinology. 177: S14. PMID 32634921 DOI: 10.1016/J.Toxicon.2019.10.061 |
0.825 |
|
| 2020 |
Hew BE, Pangburn MK, Vogel CW, Fritzinger DC. Identification of intermolecular bonds between factor B and Cobra Venom Factor important for C3 convertase stability. Toxicon : Official Journal of the International Society On Toxinology. PMID 32526239 DOI: 10.1016/J.Toxicon.2020.05.025 |
0.834 |
|
| 2019 |
Hew BE, Fritzinger DC, Pangburn MK, Vogel CW. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins. Toxicon : Official Journal of the International Society On Toxinology. 167: 106-116. PMID 31207349 DOI: 10.1016/J.Toxicon.2019.06.017 |
0.818 |
|
| 2019 |
Vogel C, Fitzinger DC, Hew BE. Cobra venom factor: A lead venom component for the development of a biologic for the treatment of complement-mediated diseases Toxicon. 159: S6. DOI: 10.1016/J.Toxicon.2018.11.333 |
0.738 |
|
| 2018 |
Ing M, Hew BE, Fritzinger DC, Delignat S, Lacroix-Desmazes S, Vogel CW, Rayes J. Absence of a neutralizing antibody response to humanized cobra venom factor in mice. Molecular Immunology. 97: 1-7. PMID 29525557 DOI: 10.1016/J.Molimm.2018.02.018 |
0.778 |
|
| 2017 |
Rayes J, Ing M, Delignat S, Peyron I, Gilardin L, Vogel CW, Fritzinger DC, Frémeaux-Bacchi V, Kaveri SV, Roumenina LT, Lacroix-Desmazes S. Complement C3 is a novel modulator of the anti-FVIII immune response. Haematologica. PMID 29146705 DOI: 10.3324/Haematol.2017.165720 |
0.474 |
|
| 2016 |
Vogel C, Fritzinger DC. Humanized cobra venom factor: Development of a therapeutic agent from a venom component Toxicon. 117: 107. DOI: 10.1016/J.Toxicon.2016.04.017 |
0.411 |
|
| 2016 |
Ing M, Hew BE, Fritzinger DC, Peyron I, Kaveri SV, Lacroix-Desmazes S, Vogel C, Rayes J. Lack of functional immunogenicity of humanized cobra venom factor in mice: Analysis of the IgG response against CVF and human C3 Immunobiology. 221: 1139-1140. DOI: 10.1016/J.Imbio.2016.06.035 |
0.794 |
|
| 2015 |
Vogel CW, Fritzinger DC, Gorsuch WB, Stahl GL. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases. Thrombosis and Haemostasis. 113: 548-52. PMID 25031089 DOI: 10.1160/TH14-04-0300 |
0.349 |
|
| 2014 |
Vogel CW, Finnegan PW, Fritzinger DC. Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models. Molecular Immunology. 61: 191-203. PMID 25062833 DOI: 10.1016/J.Molimm.2014.06.035 |
0.561 |
|
| 2012 |
Hew BE, Wehrhahn D, Fritzinger DC, Vogel CW. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor. Toxicon : Official Journal of the International Society On Toxinology. 60: 632-47. PMID 22609532 DOI: 10.1016/J.Toxicon.2012.05.004 |
0.82 |
|
| 2012 |
Fritzinger DC, Hew BE, Vogel C. 24. Recombinant Hybrid Proteins from Cobra Venom Factor and Human C3: Promising Agents for Therapeutic Intervention in Complement-Mediated Diseases Toxicon. 60: 107. DOI: 10.1016/J.Toxicon.2012.04.025 |
0.8 |
|
| 2010 |
Fritzinger DC, Dean R, Meschter C, Wong K, Halter R, Borlak J, St John WD, Vogel CW. Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degeneration. Advances in Experimental Medicine and Biology. 703: 151-62. PMID 20711713 DOI: 10.1007/978-1-4419-5635-4_11 |
0.32 |
|
| 2010 |
Vogel CW, Fritzinger DC. Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion. Toxicon : Official Journal of the International Society On Toxinology. 56: 1198-222. PMID 20417224 DOI: 10.1016/J.Toxicon.2010.04.007 |
0.589 |
|
| 2010 |
Fritzinger DC, Damaj BB, Wong K, Vogel C, Finnegan PW. Pharmacokinetics of humanized cobra venom factor in mice Molecular Immunology. 47: 2268-2269. DOI: 10.1016/J.Molimm.2010.05.211 |
0.388 |
|
| 2010 |
Hew BE, Wong K, Lee JQ, Pangburn M, Vogel C, Fritzinger DC. Understanding the structural basis of convertase stability: Fine mapping of residues required for CVF-like activity in human C3/CVF hybrid proteins Molecular Immunology. 47: 2257-2257. DOI: 10.1016/J.Molimm.2010.05.179 |
0.531 |
|
| 2009 |
Wang SY, Veeramani S, Racila E, Cagley J, Fritzinger DC, Vogel CW, St John W, Weiner GJ. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood. 114: 5322-30. PMID 19805620 DOI: 10.1182/blood-2009-01-200469 |
0.328 |
|
| 2009 |
Gorsuch WB, Guikema BJ, Fritzinger DC, Vogel CW, Stahl GL. Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury. Molecular Immunology. 47: 506-10. PMID 19747734 DOI: 10.1016/J.Molimm.2009.08.017 |
0.504 |
|
| 2009 |
Janssen BJ, Gomes L, Koning RI, Svergun DI, Koster AJ, Fritzinger DC, Vogel CW, Gros P. Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex. The Embo Journal. 28: 2469-78. PMID 19574954 DOI: 10.1038/Emboj.2009.184 |
0.442 |
|
| 2009 |
Fritzinger DC, Hew BE, Thorne M, Pangburn MK, Janssen BJ, Gros P, Vogel CW. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion. Developmental and Comparative Immunology. 33: 105-16. PMID 18760301 DOI: 10.1016/J.Dci.2008.07.006 |
0.834 |
|
| 2008 |
Fritzinger DC, Hew BE, Lee JQ, Newhouse J, Alam M, Ciallella JR, Bowers M, Gorsuch WB, Guikema BJ, Stahl GL, Vogel CW. Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents. Advances in Experimental Medicine and Biology. 632: 293-307. PMID 19025130 DOI: 10.1007/978-0-387-78952-1_21 |
0.819 |
|
| 2008 |
Fritzinger D, Ferreira V, Hew B, John WS, Pangburn M, Vogel C. A novel concept for the treatment of paroxysmal nocturnal haemoglobinuria (PNH): Complement depletion with a human C3 derivative with cobra venom factor-like activity prevents lysis of PNH erythrocytes Molecular Immunology. 45: 4177. DOI: 10.1016/J.Molimm.2008.08.245 |
0.81 |
|
| 2008 |
Hew B, Lee J, Awakuni J, Fritzinger D, Vogel C. Human C3/cobra venom factor hybrid proteins for therapeutic complement depletion: Fine mapping of structure/function relationships Molecular Immunology. 45: 4120. DOI: 10.1016/J.Molimm.2008.08.075 |
0.807 |
|
| 2008 |
Fritzinger D, Hew B, Lee J, John WS, Scaife M, Wilson S, Vogel C. Human C3/cobra venom factor hybrid proteins for therapeutic complement depletion: In vivo activity and lack of toxicity in primates Molecular Immunology. 45: 4112. DOI: 10.1016/J.Molimm.2008.08.052 |
0.827 |
|
| 2008 |
Janssen B, Gomes L, Fritzinger D, Vogel C, Meeldijk H, Svergun D, Koning R, Koster A, Gros P. Structure of factor B in complex with cobra venom factor gives insights into convertase formation Molecular Immunology. 45: 4096. DOI: 10.1016/J.Molimm.2008.08.004 |
0.345 |
|
| 2007 |
Vogel CW, Fritzinger DC. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion. Current Pharmaceutical Design. 13: 2916-26. PMID 17979736 DOI: 10.2174/138161207782023748 |
0.659 |
|
| 2007 |
Fritzinger DC, Hew BE, Lee JQ, Vogel C. Human C3/Cobra Venom Factor hybrid proteins for therapeutic complement depletion: In vivo activity and fine mapping of important domains Molecular Immunology. 44: 3945. DOI: 10.1016/J.Molimm.2007.06.087 |
0.806 |
|
| 2007 |
Fritzinger DC, Hew BE, Janssen BJ, Gros P, Vogel C. Location of amino acid residues important for cobra venom factor function mapped on the three-dimensional structure of complement components C3 and C3c Molecular Immunology. 44: 172. DOI: 10.1016/J.Molimm.2006.07.062 |
0.476 |
|
| 2004 |
Vogel CW. Preparation of immunoconjugates using antibody oligosaccharide moieties. Methods in Molecular Biology (Clifton, N.J.). 283: 87-108. PMID 15197304 DOI: 10.1385/1-59259-813-7:087 |
0.344 |
|
| 2004 |
Vogel CW, Fritzinger DC, Hew BE, Thorne M, Bammert H. Recombinant cobra venom factor. Molecular Immunology. 41: 191-9. PMID 15159065 DOI: 10.1016/J.Molimm.2004.03.011 |
0.817 |
|
| 2004 |
Kock MA, Hew BE, Bammert H, Fritzinger DC, Vogel CW. Structure and function of recombinant cobra venom factor. The Journal of Biological Chemistry. 279: 30836-43. PMID 15131128 DOI: 10.1074/Jbc.M403196200 |
0.822 |
|
| 2002 |
Andrä J, Halter R, Kock MA, Niemann H, Vogel CW, Paul D. Generation and characterization of transgenic mice expressing cobra venom factor. Molecular Immunology. 39: 357-65. PMID 12220893 DOI: 10.1016/S0161-5890(02)00107-4 |
0.409 |
|
| 2001 |
David K, Heiligtag S, Ollert MW, Teppke M, Vogel C, Bredehorst R. Initial characterization of the apoptosis‐inducing receptor for natural human anti‐neuroblastoma IgM Medical and Pediatric Oncology. 36: 251-257. PMID 11464898 DOI: 10.1002/1096-911X(20010101)36:1<251::Aid-Mpo1062>3.0.Co;2-Z |
0.448 |
|
| 2001 |
Gowda DC, Glushka J, Van Halbeek H, Thotakura RN, Bredehorst R, Vogel CW. N-linked oligosaccharides of cobra venom factor novel α(1-3)galactosylated LeX structures Glycobiology. 11: 195-208. PMID 11320058 DOI: 10.1093/Glycob/11.3.195 |
0.376 |
|
| 2001 |
Sharma S, Jabeen T, Singh RK, Bredhorst R, Vogel CW, Betzel C, Singh TP. Structural studies on the cobra venom factor: isolation, purification, crystallization and preliminary crystallographic analysis. Acta Crystallographica. Section D, Biological Crystallography. 57: 596-8. PMID 11264593 DOI: 10.1107/S0907444901001342 |
0.515 |
|
| 2000 |
Wehrhahn D, M. Meiling K, Fritzinger DC, Bredehorst R, Andrä J, Vogel C. Analysis of the structure/function relationship of Cobra Venom Factor (CVF) and C3: Generation of CVF/cobra-C3 hybrid proteins Immunopharmacology. 49: 94. DOI: 10.1016/S0162-3109(00)80281-7 |
0.584 |
|
| 1998 |
Bambai B, Teppke M, Bredehorst R, Vogel C. cDNA cloning and expression of cobrin, the C3-cleaving metalloprotease from cobra venom Molecular Immunology. 35: 408. DOI: 10.1016/S0161-5890(98)90843-4 |
0.443 |
|
| 1997 |
Juhl H, Petrella EC, Cheung NV, Bredehorst R, Vogel C. Title>Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells Immunobiology. 197: 444-459. PMID 9413745 DOI: 10.1016/S0171-2985(97)80078-2 |
0.341 |
|
| 1996 |
Vogel C, Bredehorst R, Fritzinger DC, Grunwald T, Ziegelmüller P, Kock MA. Structure and Function of Cobra Venom Factor, the Complement-Activating Protein in Cobra Venom Advances in Experimental Medicine and Biology. 391: 97-114. PMID 8726051 DOI: 10.1007/978-1-4613-0361-9_6 |
0.44 |
|
| 1996 |
David K, Ollert MW, Juhl H, Vollmert C, Erttmann R, Vogel C, Bredehorst R. Growth arrest of solid human neuroblastoma xenografts in nude rats by natural IgM from healthy humans Nature Medicine. 2: 686-689. PMID 8640561 DOI: 10.1038/Nm0696-686 |
0.353 |
|
| 1995 |
Fritzinger DC, Bredehorst R, Vogel CW. Molecular cloning and derived primary structure of cobra venom factor. Proceedings of the National Academy of Sciences of the United States of America. 91: 12775-9. PMID 7809120 DOI: 10.1073/pnas.91.26.12775 |
0.425 |
|
| 1995 |
Zara J, Pomato N, McCabe RP, Bredehorst R, Vogel C. Cobra venom factor immunoconjugates: effects of carbohydrate-directed versus amino group-directed conjugation. Bioconjugate Chemistry. 6: 367-372. PMID 7578355 DOI: 10.1021/Bc00034A005 |
0.363 |
|
| 1995 |
Fritzinger DC, Bredehorst R, Vogel C. Corrections: Molecular Cloning and Derived Primary Structure of Cobra Venom Factor Proceedings of the National Academy of Sciences of the United States of America. 92: 7605-7605. DOI: 10.1073/Pnas.92.16.7605-A |
0.342 |
|
| 1993 |
Ollert MW, David K, Bredehorst R, Vogel C. A novel function of complement factor H: restriction of classical pathway activation Molecular Immunology. 30: 40. DOI: 10.1016/0161-5890(93)90321-2 |
0.362 |
|
| 1992 |
Gowda DC, Schultz M, Bredehorst R, Vogel C. Structure of the major oligosaccharide of cobra venom factor Molecular Immunology. 29: 335-342. PMID 1557044 DOI: 10.1016/0161-5890(92)90020-X |
0.339 |
|
| 1991 |
Zara JJ, Wood RD, Boon P, Kim CH, Pomato N, Bredehorst R, Vogel CW. A carbohydrate-directed heterobifunctional cross-linking reagent for the synthesis of immunoconjugates. Analytical Biochemistry. 194: 156-62. PMID 1867379 DOI: 10.1016/0003-2697(91)90163-N |
0.309 |
|
| 1990 |
Juhl H, Petrella EC, Cheung NV, Bredehorst R, vogel C. Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic. Molecular Immunology. 27: 957-964. PMID 2233757 DOI: 10.1016/0161-5890(90)90118-J |
0.323 |
|
| 1987 |
Petrella EC, Wilkie SD, Smith CA, Morgan AC, Vogel CW. Antibody conjugates with cobra venom factor. Synthesis and biochemical characterization. Journal of Immunological Methods. 104: 159-72. PMID 3500233 DOI: 10.1016/0022-1759(87)90500-X |
0.419 |
|
| 1986 |
Ryan AF, Catanzaro A, Wasserman SI, Harris JP, Vogel CW. The effect of complement depletion on immunologically mediated middle ear effusion and inflammation. Clinical Immunology and Immunopathology. 40: 410-21. PMID 3731540 DOI: 10.1016/0090-1229(86)90185-6 |
0.31 |
|
| 1986 |
Panneerselvam M, Bredehorst R, Vogel C. Immobilized doxorubicin increases the complement susceptibility of human melanoma cells by protecting complement component C3b against inactivation Proceedings of the National Academy of Sciences of the United States of America. 83: 9144-9148. PMID 3466179 DOI: 10.1073/Pnas.83.23.9144 |
0.335 |
|
| 1985 |
Vogel C, Müller-Eberhard HJ. The cobra complement system: II. The membrane attack complex. Developmental and Comparative Immunology. 9: 327-333. PMID 4018344 DOI: 10.1016/0145-305X(85)90123-5 |
0.312 |
|
| 1985 |
Vogel C, Müller-Eberhard HJ. The cobra complement system: I. The alternative pathway of activation Developmental and Comparative Immunology. 9: 311-325. PMID 3894085 DOI: 10.1016/0145-305X(85)90122-3 |
0.492 |
|
| 1982 |
Vogel C, Müller-Eberhard HJ. A new concept of inducing immune cytolysis: Killing of tumor cells via the alternative pathway induced by a covalent hybrid of monoclonal antibody and cobra venom factor Molecular Immunology. 19: 1407. DOI: 10.1016/0161-5890(82)90169-9 |
0.306 |
|
| Show low-probability matches. |